CCS Research
CCS Publications
  • Zhang C, Doherty JA, Burgess S, Hung RJ, Lindstrom S, Kraft P, Gong J, Amos CI, Sellers TA, Monteiro AN, et al: Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Human molecular genetics 2015.

  • Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, Westphal M, Lamszus K, Kim SZ, Becker N, et al: Identification of HERC5 and its potential role in NSCLC progression. International journal of cancer Journal international du cancer 2015, 136:2264-2272.

  • Wolkerstorfer S, Schwaiger E, Rinnerthaler M, Karina Gratz I, Zoegg T, Brandstetter H, Achatz-Straussberger G: HAX1 deletion impairs BCR internalization and leads to delayed BCR-mediated apoptosis. Cell Mol Immunol 2015.

  • Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, et al: The significance of pre-treatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: A dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol 2015.

  • Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, et al: Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015, 125:1091-1097.

  • Sochalska M, Tuzlak S, Egle A, Villunger A: Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. The FEBS journal 2015, 282:834-849.

  • Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, et al: Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015, 521:94-98.

  • Schutz A, Roser K, Klitzsch J, Lieder F, Aberger F, Gruber W, Mueller KM, Pupyshev A, Moriggl R, Friedrich K: Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. Translational oncology 2015, 8:97-105.

  • Schultz L, Zurich MG, Culot M, da Costa A, Landry C, Bellwon P, Kristl T, Hormann K, Ruzek S, Aiche S, et al: Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicol In Vitro 2015.

  • Schmidt A, Denier N, Magon S, Radue EW, Huber CG, Riecher-Rossler A, Wiesbeck GA, Lang UE, Borgwardt S, Walter M: Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution. Transl Psychiatry 2015, 5:e533.

  • Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G: A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? Annals of hematology 2015, 94:345-346.

  • Schiefer AI, Vesely P, Hassler MR, Egger G, Kenner L: The role of AP-1 and epigenetics in ALCL. Front Biosci (Schol Ed) 2015, 7:226-235.

  • Rauch I, Rosebrock F, Hainzl E, Heider S, Majoros A, Wienerroither S, Strobl B, Stockinger S, Kenner L, Muller M, Decker T: Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons. Mol Cell Biol 2015, 35:2332-2343.

  • Ranninger C, Rurik M, Limonciel A, Ruzek S, Reischl R, Wilmes A, Jennings P, Hewitt P, Dekant W, Kohlbacher O, Huber CG: Nephron Toxicity Profiling via Untargeted Metabolome Analysis Employing a High Performance Liquid Chromatography-Mass Spectrometry-based Experimental and Computational Pipeline. The Journal of biological chemistry 2015, 290:19121-19132.

  • Ramos F, Thepot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martinez-Robles V, et al: Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia research 2015, 39:296-306.

  • Poirier JG, Brennan P, McKay JD, Spitz MR, Bickeboller H, Risch A, Liu G, Le Marchand L, Tworoger S, McLaughlin J, et al: Informed Genome-Wide Association Analysis With Family History As a Secondary Phenotype Identifies Novel Loci of Lung Cancer. Genetic epidemiology 2015.

  • Pleyer L, Greil R: Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev 2015:1-28.

  • Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, et al: Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. Anticancer research 2015, 35:517-521.

  • Perna AM, Rodrigues T, Schmidt TP, Bohm M, Stutz K, Reker D, Pfeiffer B, Altmann KH, Backert S, Wessler S, Schneider G: Fragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of Helicobacter Pylori HtrA. Angewandte Chemie 2015, 54:10244-10248.

  • Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marie IJ, Hassler MR, Javaheri T, Aksoy O, et al: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature communications 2015, 6:7736.

  • Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, et al: Myeloid promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology 2015, 4:e998529.

  • Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, et al: AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget 2015.

  • Nivarthi H, Prchal-Murphy M, Swoboda A, Hager M, Schlederer M, Kenner L, Tuckermann J, Sexl V, Moriggl R, Ermakova O: Stat5 gene dosage in T cells modulates CD8+ T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy 2015, 70:67-79.

  • Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, et al: Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene 2015, 34:1843-1852.

  • Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, et al: Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of pathology 2015, 236:445-456.

  • Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, et al: Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia & lymphoma 2015, 56:353-360.

  • Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, et al: A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. British journal of haematology 2015, 168:239-245.

  • Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T: The role of polycomb repressive complexes in biliary tract cancer. Expert opinion on therapeutic targets 2015, 19:363-375.

  • Mathieu R, Klatte T, Lucca I, Beutcha AM, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, et al: Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int 2015.

  • Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, et al: Lobatin B inhibits NPM/ALK and NF-kappaB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. Cancer letters 2015, 356:994-1006.

  • Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, Greil R, Hartmann TN, Aberger F: Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene 2015.

  • Johrer K, Ploner C, Thangavadivel S, Wuggenig P, Greil R: Adipocyte-derived players in hematologic tumors: useful novel targets? Expert Opin Biol Ther 2015, 15:61-77.

  • Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G: VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. Leukemia & lymphoma 2015:1-3.

  • Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, et al: Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature communications 2015, 6:6285.

  • Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, et al: Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015, 26:313-320.

  • Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F: IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up. International journal of cancer Journal international du cancer 2015, 136:1193-1201.

  • Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F: IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer-Results of a case series after 5-year follow-up. International journal of cancer Journal international du cancer 2015, 136:1193-1201.

  • Engelmann JC, Amann T, Ott-Rotzer B, Nutzel M, Reinders Y, Reinders J, Thasler WE, Kristl T, Teufel A, Huber CG, et al: Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFkappaB Signaling in Hepatocellular Carcinoma. PLoS Comput Biol 2015, 11:e1004293.

  • Dueregger A, Schopf B, Eder T, Hofer J, Gnaiger E, Aufinger A, Kenner L, Perktold B, Ramoner R, Klocker H, Eder IE: Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate. PloS one 2015, 10:e0135704.

  • Dall E, Fegg JC, Briza P, Brandstetter H: Structure and mechanism of an aspartimide-dependent Peptide ligase in human legumain. Angewandte Chemie 2015, 54:2917-2921.

  • Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, et al: Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer cell 2015, 27:516-532.

  • Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, et al: CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. Journal of the National Cancer Institute 2015, 107.

  • Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nosslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstocker M: 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener klinische Wochenschrift 2015, 127:12-15.

  • Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, et al: Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015, 33:179-190.

  • Birner P, Egger G, Merkel O, Kenner L: JunB and PTEN in prostate cancer: 'loss is nothing else than change'. Cell death and differentiation 2015, 22:522-523.

  • Aiche S, Sachsenberg T, Kenar E, Walzer M, Wiswedel B, Kristl T, Boyles M, Duschl A, Huber CG, Berthold MR, et al: Workflows for automated downstream data analysis and visualization in large-scale computational mass spectrometry. Proteomics 2015.

  • Wagner A, Denzer UW, Neureiter D, Kiesslich T, Puespoeck A, Rauws EA, Emmanuel K, Degenhardt N, Frick U, Beuers U, et al: Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. Hepatology 2015.

  • Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, et al: The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol 2015.

  • Swierczynski S, Klieser E, Illig R, Alinger-Scharinger B, Kiesslich T, Neureiter D: Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015, 15:651-664.

  • Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, et al: Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer. Molecular cancer therapeutics 2015.

  • Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G: A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? Annals of hematology 2015, 94:345-346.

  • Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, Sperl W, Kofler B: Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model. PloS one 2015, 10:e0129802.

  • Menendez-Castro C, Cordasic N, Neureiter D, Amann K, Marek I, Volkert G, Stintzing S, Jahn A, Rascher W, Hilgers KF, Hartner A: Under-expression of alpha8 integrin aggravates experimental atherosclerosis. The Journal of pathology 2015, 236:5-16.

  • Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, et al: Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia & lymphoma 2015, 56:353-360.

  • Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, et al: A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. British journal of haematology 2015, 168:239-245.

  • Mayr C, Wagner A, Stoecklinger A, Jakab M, Illig R, Berr F, Pichler M, P DIF, Ocker M, Neureiter D, Kiesslich T: 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. Anticancer research 2015, 35:4697-4705.

  • Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illig R, Berr F, Kiesslich T: The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med 2015, 15:194.

  • Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T: The role of polycomb repressive complexes in biliary tract cancer. Expert opinion on therapeutic targets 2015, 19:363-375.

  • Mayr C, Neureiter D, Pichler M, Berr F, Wagner A, Kiesslich T, Namberger K: Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine. Mol Med Rep 2015, 12:2247-2252.

  • Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G: VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. Leukemia & lymphoma 2015:1-3.

  • Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P: The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Molecular carcinogenesis 2015, 54:585-597.

  • Gahr S, Mayr C, Kiesslich T, Illig R, Neureiter D, Alinger B, Ganslmayer M, Wissniowski T, Fazio PD, Montalbano R, et al: The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International journal of oncology 2015, 47:963-970.

Translational cancer research at CCS

Bench-to-bedside and bedside-to-bench work

The scientific strategy and conceptual organization of CCS allows both the validation of basic research findings in clinical settings (bench to bedside) and the detailed molecular analysis of clinical observations in predictive in vitro and in vivo model systems (bedside to bench). This bidirectional research strategy accelerates the discovery of novel and innovative therapeutic approaches for personalized cancer therapy. 

Funding & Support

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at

Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at